SCHEMBL2997612

SCHEMBL2997612

O=S(=O)(c1c(F)c(Br)cc(F)c1Br)N1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 2/20 0.40
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 4/20 0.38
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.33
DNM1L O00429 1/20 0.33
HTR6 P50406 1/20 0.33
PKM P14618 2/20 0.33
PKLR P30613 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006071 0.92 SMN1; SMN2 (0.37) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3018343 0.91 SMN1; SMN2 (0.37) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3021199 0.91 ALDH1A1 (0.37) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3017349 0.91 ALDH1A1 (0.37) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3004059 0.90 MAPT (0.37) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3017973 0.90 ALDH1A1 (0.38) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3014683 0.90 ALDH1A1 (0.39) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3012638 0.89 ALDH1A1 (0.36) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3009439 0.89 MAPT (0.42) KMT2ALMNAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL3019065 0.88 PROKR1 (0.38) KMT2ALMNAMEN1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885LMNA 80/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.